Sonoma Pharmaceuticals, Inc.
SNOAAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Maxim Group | downgrade | Buy →Hold | Nov 25, 2020 |
| Benchmark | maintain | Speculative Buy →Buy | Nov 25, 2020 |
| Maxim Group | maintain | Buy | Nov 25, 2020 |
| Maxim Group | downgrade | Buy →Hold | Mar 6, 2018 |
| Benchmark | maintain | Speculative Buy →Buy | Dec 28, 2017 |
| Maxim Group | maintain | Buy | Nov 10, 2017 |
Earnings History
Next report: Nov 16, 2026 · EPS est. $-0.10| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $0.02 | $-0.30 | $6.4M | $5.0M |
| Jun 16, 2026 | $-0.33 | $-0.24 | $5.6M | $5.6M |
| Feb 4, 2026 | $-0.48 | $-0.29 | $4.3M | $5.5M |
| Nov 6, 2025 | $-0.32 | $-0.31 | $5.6M | $4.3M |
| Aug 7, 2025 | $-0.76 | $-0.51 | $4.0M | $4.0M |
| Jun 16, 2025 | $-0.15 | $-0.73 | $3.8M | $4.4M |
| Feb 6, 2025 | $-0.59 | $-0.80 | $3.6M | $4.1M |
| Nov 11, 2024 | $-0.59 | $-0.80 | $3.6M | $3.8M |
News
Orion OYJ (OTCMKTS:ORINY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations. Profitability This table compares Orion OYJ and Sonoma
Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Indivior (NASDAQ: INDV - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Insider and Institutional Ownership 1.9% of Sonoma Pharmaceuticals shares
Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings. Institutional and Insider Ownership 86.2% of Harmony Biosciences